SwePub
Sök i LIBRIS databas

  Utökad sökning

L773:1557 3125
 

Sökning: L773:1557 3125 > Convergent Evolutio...

  • Pienta, Kenneth JJohns Hopkins University School of Medicine (författare)

Convergent Evolution, Evolving Evolvability, and the Origins of Lethal Cancer

  • Artikel/kapitelEngelska2020

Förlag, utgivningsår, omfång ...

  • 2020
  • 10 s.

Nummerbeteckningar

  • LIBRIS-ID:oai:lup.lub.lu.se:f8dc6977-2e18-4b82-9cc1-3c1bbc34f9e1
  • https://lup.lub.lu.se/record/f8dc6977-2e18-4b82-9cc1-3c1bbc34f9e1URI
  • https://doi.org/10.1158/1541-7786.MCR-19-1158DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:for swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • Advances in curative treatment to remove the primary tumor have increased survival of localized cancers for most solid tumor types, yet cancers that have spread are typically incurable and account for >90% of cancer-related deaths. Metastatic disease remains incurable because, somehow, tumors evolve resistance to all known compounds, including therapies. In all of these incurable patients, de novo lethal cancer evolves capacities for both metastasis and resistance. Therefore, cancers in different patients appear to follow the same eco-evolutionary path that independently manifests in affected patients. This convergent outcome, that always includes the ability to metastasize and exhibit resistance, demands an explanation beyond the slow and steady accrual of stochastic mutations. The common denominator may be that cancer starts as a speciation event when a unicellular protist breaks away from its multicellular host and initiates a cancer clade within the patient. As the cancer cells speciate and diversify further, some evolve the capacity to evolve: evolvability. Evolvability becomes a heritable trait that influences the available variation of other phenotypes that can then be acted upon by natural selection. Evolving evolvability may be an adaptation for cancer cells. By generating and maintaining considerable heritable variation, the cancer clade can, with high certainty, serendipitously produce cells resistant to therapy and cells capable of metastasizing. Understanding that cancer cells can swiftly evolve responses to novel and varied stressors create opportunities for adaptive therapy, double-bind therapies, and extinction therapies; all involving strategic decision making that steers and anticipates the convergent coevolutionary responses of the cancers.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Hammarlund, Emma ULund University,Lunds universitet,Avdelningen för translationell cancerforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Division of Translational Cancer Research,Department of Laboratory Medicine,Faculty of Medicine,LUCC: Lund University Cancer Centre,Other Strong Research Environments,University of Southern Denmark(Swepub:lu)med-ehd (författare)
  • Axelrod, RobertUniversity of Michigan (författare)
  • Amend, Sarah RJohns Hopkins University School of Medicine (författare)
  • Brown, Joel SH. Lee Moffitt Cancer Center & Research Institute (författare)
  • Johns Hopkins University School of MedicineAvdelningen för translationell cancerforskning (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Molecular cancer research : MCR18:6, s. 801-8101557-3125

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy